Skip to content

Released Aug 8, 2023, after the close

10-Q filed Aug 8, 2023, 39 days after period end · 0001628280-23-028287

Q2 2023 · 10-Q
Revenue$27.67M+47.3% vs Q2 2022+10.1% vs Q1 2023
Net Income-$17.04MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.22N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$13,602,000+207.3%
Operating Income-$17,449,000N/M
Operating Cash Flowderived-$9,329,000N/M
Free Cash Flowderived-$10,167,000N/M
Margins · derived
Gross margin49.2%+25.6 pt vs Q2 2022
Operating margin-63.1%+142.3 pt vs Q2 2022
Net margin-61.6%+276.8 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$27.67M$18.78M$31.02M$26.06M
Net Income-$17.04M-$63.54M-$17.14M-$13.02M
EPS Diluted-$0.22-$0.82-$0.23-$0.18

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR